Home › Funds › D. E. Shaw & Co › AZN

D. E. Shaw & Co position in AZN

ASTRAZENECA PLC · Health Care

D. E. Shaw & Co reported holding 4,775,972 shares of AZN (ASTRAZENECA PLC) in its Q3 2026 13F filing — a position valued at US$771.2M, representing 1.09% of its reported portfolio and ranking #4 among its reported holdings. D. E. Shaw & Co has disclosed AZN holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)4.78M sh
Reported value held$771.18M
Portfolio Weight1.09%
First reportedQ3 2021
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How D. E. Shaw & Co's AZN position evolved

D. E. Shaw & Co first disclosed a stake in AZN in Q3 2021 at 1,373,944 shares (US$82.5M). The position peaked in Q3 2026 at 4,775,972 shares, worth US$771.2M. Across 21 filings, D. E. Shaw & Co increased the stake 11 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 4,775,972 shares valued at US$771.2M — an increase of 3,681,379 shares quarter over quarter.. Notable position changes include a 3454% increase in Q3 2022 (shares rose 24% over the following quarter), a 3130% increase in Q3 2024 (shares fell 16% over the following quarter), a 4277% increase in Q2 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 1.37M $82.52M New
Q4 2021 909.98K $53.01M Reduce
Q1 2022 236.95K $15.72M Reduce
Q2 2022 9.84K $650.00K Reduce
Q3 2022 349.87K $19.19M Add
Q4 2022 665.91K $45.15M Add
Q1 2023 22.86K $1.59M Reduce
Q2 2023 43.41K $3.11M Add
Q3 2023 720.28K $48.78M Add
Q4 2023 1.57M $105.59M Add
Q1 2024 16.72K $1.13M Reduce
Q2 2024 50.15K $3.91M Add
Q3 2024 1.62M $126.20M Add
Q4 2024 4.84M $317.36M Add
Q1 2025 1.70M $125.00M Reduce
Q2 2025 1.97M $137.58M Add
Q3 2025 246.53K $18.91M Reduce
Q4 2025 53.24K $4.89M Reduce
Q1 2026 25.00K $4.93M Reduce
Q2 2026 1.09M $207.56M Add
Q3 2026 4.78M $771.18M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AZN and 13F data

AZN (ASTRAZENECA PLC) is a Health Care company. 56 other funds we track also report a position in AZN — the largest reported positions include INVESTOR AB (US$8.33B), Norges Bank Investment Management (US$6.33B), Capital World Investors (US$5.06B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AZN

All AZN fund holders →

FAQ

How long has D. E. Shaw & Co held AZN?

D. E. Shaw & Co has disclosed AZN holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is D. E. Shaw & Co's current position in AZN?

As of Q3 2026, D. E. Shaw & Co holds 4.78M shares of AZN (ASTRAZENECA PLC), valued at $771.18M, representing 1.09% of its reported portfolio and ranking #4.

Has D. E. Shaw & Co been buying or selling AZN?

In the latest 13F filing (Q3 2026), D. E. Shaw & Co increased its position in AZN. The position peaked in Q3 2026 at 4.78M shares.

Which other funds hold AZN?

Other major institutional holders of AZN include INVESTOR AB, Norges Bank Investment Management, Capital World Investors, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.